Welcoming the 2023 Eid al-Fitr Homecoming, Phapros Prepares Tens of Thousands of Product Packages and Antimo Posts

JAKARTA, April 11, 2023 – PT Phapros Tbk, which is part of the large Holding of State-Owned Pharmaceutical Companies, is preparing various programs to enliven the 2023 Eid al-Fitr homecoming moment with its legendary product, Antimo. The President Director of PT Phapros Tbk, Hadi Kardoko, said that based on data from the Indonesian Ministry of Transportation, an estimated 123.8 million people are expected to travel for the homecoming tradition, an increase from 85.5 million people in the previous year.

"This moment is important for us together with Antimo, which has been a traveling companion for Indonesian families for more than 50 years. Therefore, we have prepared various programs to ensure the safe travel of people returning to their hometowns," said Hadi, as he is familiarly called. Hadi said that the company has cooperated with several parties to participate in the free homecoming program.

"We have prepared tens of thousands of products that will be distributed in the free homecoming program, one of which is in collaboration with the Ministry of State-Owned Enterprises. These products are also expected to maintain the immunity of travelers and keep them fit during the Eid al-Fitr celebration with their families. We have also prepared Antimo posts at several points such as Rest Area KM 57 and KM 379 where travelers can enjoy various entertainment while taking a break," added Hadi.

The stock code issuer PEHA is also collaborating with several Key Opinion Leaders to educate through social media about safe and comfortable homecoming travel. Hadi also reminded the public to always maintain their health and safety while traveling. "If you feel tired while driving, take a rest immediately, and don't forget to consume nutritious food and additional multivitamins with Vitamin C and E content to maintain the body's immunity," he said.

Previously, based on financial reports audited by the Public Accounting Firm (KAP), Phapros recorded above-average performance growth in the national pharmaceutical industry in 2022, with net sales rising by more than 11 percent and net profit significantly increasing by 143 percent compared to 2021.